Use of retinoic acid-eluting stents for preventing restenosis in an animal model

Background: The aim of this study was to evaluate the world's largest drugeluting stent registry that used the Seattle Angina Questionnaire (SAQ) to assess changes in angina frequency (AF) and quality of life (QoL) across angiographically important groups receiving exclusively XIENCE V at the index procedure. Methods: We conducted a prospective, multicenter, unrestricted real-world registry of consecutively enrolled patients undergoing percutaneous coronary intervention (PCI) with the XIENCE V stent. Asymptotic normality test comparing change from baseline values against a threshold of 10 points was used to assess the significance of changes within each group even though group mean changes in SAQ scores of ≥5 points are considered clinically significant. Results: Of the 4852 patients who had at least one valid score at baseline, 3830 (79%) completed 6-month follow-up. Mean age was 64.7±11.1 years, 69%were men, 35.3% had diabetes, and 39% had two or more diseased vessels. Shown below are SAQ AF and QoL scores at baseline and clinically relevant improvements at 6 months in the total population, near on-label and off-label subgroups, various angiographic cohorts, and four angina burden categories. Innovative analysis comparing scores within the 10Medicare geographic regions will also be presented. Conclusion:Marked improvement in patients' health statuswas observed across angiographic and angina subgroups. Those with daily or weekly angina prior to PCI with XIENCE V reported the greatest improvements in QoL.